• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • TBK1 Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • Adenosine Kinase Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

MAPK14 in Context

by Bellbrook Labs / Wednesday, 13 April 2022 / Published in Emerging Targets, Innate Immunity
Researcher Studying MAPK14

MAPK14 (or p38 alpha or SAPK2a) is a proline-directed serine/threonine kinase activated by environmental stress or inflammatory signaling. While it is a well-conserved eukaryotic gene in the mitogen-activated protein kinase family, MAPK14 doesn’t typically respond to mitogens. All the same, MAPK14 is critically involved in cardiac development, sex determination, innate and adaptive immunity, and cellular homeostasis in neural, muscular, skeletal, adipose, and hepatic tissues.

There are more than 100 proteins that are directly phosphorylated (activated) by MAPK14, both in the nucleus and cytoplasm, influencing transcription, chromatin remodeling, cell cycle control, DNA repair, mRNA translation, protein degradation, autophagy, endocytosis, cytoskeletal elements, and metabolism. Depending on cell type and state of health, these influences are proving to be immensely complex and even seemingly contradictory.1

MAPK14:  The Medium Is the Message

Canonically, MAPK14 is activated by a MAP2K-based phosphorylation cascade, typically induced by cytokine or G protein-coupled receptor docking or stressors (ROS, mechanical, or cellular damage). Non-canonically, MAPK14 can be activated via ZAP70 phosphorylation (induced by T cell receptor signaling) or binding to transforming growth factor beta activated protein 1. Given the great variety of provocations that induce MAPK14 activation and its downstream effects, dephosphorylation by various actors and negative feedback loops primarily serve to regulate its activity.2

A recently discovered pathway to MAPK14 activation involves signaling by toll-like receptor 4 (TLR4) in response to lipopolysaccharide stimulation. Lipopolysaccharide (LPS) is present on the surface of gram-negative bacteria and some viral proteins. Mice lacking functional MAPK14 in their astrocytes exhibit a diminished astroglial response to administered LPS. However, under these circumstances, microglia and neutrophil infiltration become more intense.3  Accordingly, challenging microglia with LPS stimulates TRL4 receptors and activates MAPK14. The microglial brake on inflammation and enabler of autophagy, ULK1, is then phosphorylated (inhibited) by MAPK14, initiating an innate inflammatory response.4  Infection by Covid-19 also acts via the TRL4/MAPK14 axis to trigger endotheliitis. To a considerable degree, the intensity of this response dictates the acute vascular severity of the infection and risk to a given patient’s life.5

MAPK14 Therapeutics:  Where do we go now?

While brief and appropriate responses help to repel invading organisms, prolonged engagement, outsized MAPK14 expression, or constitutive signaling can result in chronic inflammatory diseases, such as rheumatoid arthritis and chronic obstructive pulmonary disease. On the other hand, MAPK14 also exhibits cell type specific anti-inflammatory functions that attenuate particular tissue-damaging inflammatory responses. It is precisely this dual role of MAPK14 in the inflammatory response that complicates the use of systemic inhibitors to regulate chronic inflammation.6

So far, direct MAPK14 inhibitors have failed to achieve their goals in the clinic. Perhaps, inhibitors targeting specific downstream elements of MAPK14 signaling in particular tissues of interest are a way to increase effectiveness against a given pathology. Restricting the nuclear translocation of MAPK14 or finding ways to hasten its degradation in specific situations might also be promising. While it seems more likely that acute, punctuated MAPK14 inhibitors could get traction against certain cancers, chronic use of even slightly off target inhibitors against chronic inflammatory diseases causes collateral issues that will need to be addressed.1

References

  1. Canovas, B. and Nebreda, A. (2021) Diversity and Versatility of p38 Kinase Signalling in Health and Disease. Nature Reviews Molecular Cell Biology, 22, 346-366. https://www.nature.com/articles/s41580-020-00322-w
  2. Han, J. et al. (2020) An Overview of Mammalian p38 Mitogen-Activated Protein Kinases, Central Regulators of Cell Stress and Receptor Signaling. F1000Res. 9, 653, Review. https://f1000research.com/articles/9-653/v1
  3. Lo, U. et al. (2014) p38 alpha (MAPK14) Critically Regulates the Immunological Response and the Production of Specific Cytokines and Chemokines in Astrocytes. Nature Scientific Reports, 4, Article Number: 7405. https://www.nature.com/articles/srep07405
  4. She, H. et al. (2018) Release the Autophage Brake on Inflammation: The MAPK14/p38 alpha-ULK1 Pedal. Autophagy, 14(6), 1097-1098. https://doi.org/10.1080/15548627.2018.1446626
  5. Ma, Z. et al. (2022) A Human Pluripotent Stem Cell-Based Model of SARS-CoV-2 Infection Reveals an ACE2-Independent Inflammatory Activation of Vesicular Endothelial Cells Through TRL4. Stem Cell Reports, 17, 1-18. https://doi.org/10.1016/j.stemcr.2022.01.015
  6. Arthur, J.S.C. and Ley, S.C. (2013) Mitogen-Activated Kinases in Innate Immunity. Nature Reviews Immunology, 13, 679-692. https://www.nature.com/articles/nri3495
Tagged under: MAPK14

What you can read next

Targeting Oncogenic Ras: Hope on the Horizon
Greatwall: Cancer’s Great Defender?
New Target for Heart Disease and Cancer: Glucosylceramide Synthase (GCS)

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Scientist Studying ALKPK1

    The Role ALPK1 in Health and Disease

    ALPK1 (Alpha Kinase 1) is an atypical serine/th...
  • DHX36 RNA Helicase Unwinds G4 RNA Structures

    Resolving the Many Roles of DHX36

    While most researchers are familiar with canoni...
  • PRMT5 Role with Macrophages

    PRMT5 is Innately Interesting

    PRMT5 is a type II arginine methyltransferase t...
  • IRE1 Proteins in ER

    The Multifaceted Roles of IRE1 Are Unfolding

    IRE1 (Inositol-Requiring Enzyme 1) is one of th...
  • Researcher working on MAPK1 pathway

    MAPK1, An Elusive Regulator of Innate Immunity

    Mitogen-Activated Protein Kinases (MAPKs) and M...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2021 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP